PD26-07 SEQUENTIAL ENDOLUMINAL CABAZITAXEL AND GEMCITABINE WITH PEMBROLIZUMAB FOR DOCETAXEL-UNRESPONSIVE NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE UPPER AND LOWER URINARY TRACTS
Vignesh T. Packiam(Rutgers, The State University of New Jersey), Michael A. O’Donnell(University of Iowa Health Care), Ryan L. Steinberg(University of Iowa), Rohan Garje(Baptist Hospital of Miami), Adam E. Prescott, Yousef Zakharia(University of Iowa), Ian M. McElree(Vanderbilt University Medical Center)
Cited by 2
Related Papers
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
|JAMA Network Open|2023|116
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
|Journal of Clinical Oncology|2020|105